The global bisacodyl market is expected to grow at a significant CAGR of 5.9% during the forecast period of 2022 -2028. Bisacodyl is a laxative drug which is prescribed for the relief of constipation and the management of neurogenic bowel dysfunction. It works by increasing the movement of tract walls .It is also used as part of bowel preparation before medical examinations such as colonoscopy. 

The major factor for the growth of the market during the forecast period is the rising prevalence of constipation-related diseases. According to the National Institute of Digestive and Kidney diseases (NIDDK), constipation is common among all ages and populations in the US. About 16 out of 100 adults have symptoms of constipation. About 33 out of 100 adults ages 60 and older have symptoms of constipation. Thus, the prevalence of chronic constipation is driving the growth of the global bisacodyl market. 

Impact of COVID-19 on Global Bisacodyl Market 

The COVID -19 pandemic and its resultant lockdown have badly affected all major sectors of the economy. As a result, the pharmaceuticals and manufacturers of drugs have seen a decline in the demand for drugs due to drastic changes in the supply chain and import of drugs from China. For instance, India imports 70 % of API needs from china. The halt of imports has created a lot of hardships for the domestic manufacturers in manufacturing certain key APIs. 

Segmental Outlook 

The global bisacodyl market is segmented based on type and application. Based on the type, the market is segmented into high purity and low purity. Based on the application, the market is sub-segmented into constipation and neurogenic bowel dysfunction. Among these, the type segment is anticipated to hold a lucrative share in growth the market over the forecast period, as constipation is a prevalent disease among populations, wherein high purity bisacodyl drug can stimulate the digestive tract walls speeding up bowel movements within 6 – 12 hours which is further driving the growth of bisacodyl drug. 

Global Bisacodyl Market Share by Application, 2020 (%)

The Constipation Segment is Anticipated to Hold a Prominent Share in the Global Bisacodyl Market 

Constipation is a common medical condition that affects the normal life of an individual. It is estimated to affect every individual once in a lifetime. Constipation may be occasional or chronic which may last for a longer period. According to National Centre for Biotechnology Information, Chronic constipation is common gastrointestinal disorder with prevalence in the general population of approximately 20 %   worldwide and therefore its prevalence is increasing that is driving the overall market. The rise in population with sedimentary lifestyles such as eating disorders, irregular sleeping habits, and diabetes contribute to the increase in constipation. Therefore, the rise in constipation disease is directly causing a rise in the demand for bisacodyl laxative. However, excessive dosage and various side effects of bisacodyl laxative can create a threat to the global market. 

Regional Outlooks 

The global bisacodyl market is further segmented based on geography including North America, Europe, Asia Pacific, and the rest of the world. The market can be analyzed for a particular region or country level as per the requirement. The Asia Pacific regional bisacodyl market is expected to hold a prominent share owing to the presence of several key market players. 

Global Bisacodyl Market Growth, by Region 2022-2028

The Asia-Pacific region is estimated to hold the major share in the Global Bisacodyl Market 

In terms of laxative consumption, India tops in using laxative medicines or supplements. In January 2018, as per the survey conducted by Gut Health Survey, it is found that a common reason for constipation in India is its rich food culture. The findings stated that 22% of Indian population suffer from the condition, with 13 % complaining of severe constipation. 6% of the Indian population suffer from constipation associated with certain comorbidities.

Market players Outlook 

The major companies serving the Global Bisacodyl market include Cipla ltd., Dr. Reddy’s Laboratories, GlaxoSmithKline plc, LMG Pharma, Sanofi S.A and others. The players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in March 2021, Vibrant raised $7.5 million for a drug-free mechanical pill to treat constipation. The capsules are about the size of a multivitamin and can be used 2-5 times a week. The capsules connect to an app, that automatically records when a person takes a pill, upon having a bowel movement, the person notes it in the app, which then sends the monthly report to the patient's doctor. Therefore, over-the-counter drugs which contain side effects can be replaced with a mechanical pill.

The Report Covers

• Market value data analysis of 2022 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global bisacodyl market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market